CHICAGO, IL—Treating patients with type 2 diabetes and a history of stable coronary artery disease with empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), a sodium-glucose co-transporter 2 ...
Patients with type 2 diabetes treated with the SGLT2 inhibitor empagliflozin during the landmark EMPA-REG OUTCOME trial had a solidly reduced need to either start insulin treatment or intensify ...
Orexin, a neuropeptide, performs various physiological functions, including the regulation of emotion, feeding, metabolism, respiration, and sleep/wakefulness, by activating the orexin 1 receptor and ...
ORLANDO, Florida — Results from the EMPA-Kidney trial of the SGLT2 inhibitor empagliflozin in people with chronic kidney disease (CKD) with or without diabetes did more than add a second positive ...
The Empa spin-off Swiss Cluster has received the Swiss Economic Award 2026 in the "Industry/Production" category. The young ...
John B. Buse, MD, PhD: The EMPA-REG trial was a trial of empagliflozin versus placebo. It studied 2 different doses of empagliflozin, 10 mg and 25 mg once a day, versus matched placebo, and went on ...
Swiss researchers claim to have devised a functional living battery powered by the combined efforts of two types of fungi – all in a biodegradable, non-toxic 3D-printed package. I'll give you a second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results